Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 540

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson

Blood (2021) 138 (13): 1089.

https://doi.org/10.1182/blood.2021012674

Published: 2021

Journal Articles

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Wendan Xu, Philipp Berning, Georg Lenz

Blood (2021) 138 (13): 1110–1119.

https://doi.org/10.1182/blood.2020006784

Published: 2021

Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti

Blood (2021) 137 (24): 3378–3389.

https://doi.org/10.1182/blood.2020010187

Published: 2021

Includes: Supplemental data

Journal Articles

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Anne Durandy, Sven Kracker

Blood (2020) 135 (9): 638–643.

https://doi.org/10.1182/blood.2019002072

Published: 2020

Journal Articles

Analysis of Mechanisms Underlying Clonal Evolution of AML By a New Single-Cell Sequencing Platform

Ryosaku Inagaki, MSc, Masahiro Marshall Nakagawa, MD PhD, Yasuhito Nannya, MD PhD, Qi Xingxing, PhD, Lanying Zhao, MD, PhD, June Takeda, MD, Akinori Yoda, PhD, Ayana Kon, MD PhD, Hisashi Tsurumi, MD PhD, Hideki Makishima, MD PhD, Seishi Ogawa, MD PhD

Blood (2019) 134 (Supplement_1): 542.

https://doi.org/10.1182/blood-2019-126444

Published: 2019

Journal Articles

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Tony Zheng, Elizabeth R Lofurno, Sarah Elgamal, Alexander R Melrose, Jiaqing Pang, Joseph J Shatzel, MD, Owen J T McCarty, PhD, Joseph Aslan, PhD

Blood (2019) 134 (Supplement_1): 2074.

https://doi.org/10.1182/blood-2019-129066

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Tamilla Nechiporuk, PhD, Alisa Damnernsawad, PhD, Daniel Bottomly, MS, Quinlan Morrow, BS, Suyoun Choi, Sofia Beer, Stephen E Kurtz, PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 1395.

https://doi.org/10.1182/blood-2019-129117

Published: 2019

Journal Articles

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Ayako Nogami, MD PhD BPharm, Daisuke Watanabe, MD, Keigo Okada, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Toshikage Nagao, MD, PhD, Shuji Tohda, MD, PhD, Osamu Miura, MD, PhD

Blood (2019) 134 (Supplement_1): 1425.

https://doi.org/10.1182/blood-2019-123183

Published: 2019

Journal Articles

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Xiaoyang Su, PhD, Ying Chen, PhD, Maisarah Mokhtar, B.S, Gregory Dolnikowski, Frederick Lansigan, MD, William B Kinlaw, III, MD, Sandeep Dave, MD, Andrew M. Evens, DO, MSc

Blood (2019) 134 (Supplement_1): 1573.

https://doi.org/10.1182/blood-2019-126382

Published: 2019

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Class I PI3K Is Required for HSC Differentiation

Kristina Ames, PhD, Imit Kaur, PhD, Meng Tong, Shayda Hemmati, PhD, Ellen Tein, Shira Glushakow-Smith, Lindsay Gurska, Kira Gritsman, MD PhD

Blood (2019) 134 (Supplement_1): 2461.

https://doi.org/10.1182/blood-2019-123823

Published: 2019

Journal Articles

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Chunfen Zhang, MD, Ritul Sharma, MSc., Thakur Satbir, PhD, Allison Cheney, Olena Vaske, PhD, Lauren Sanders, Jessica Boklan, MD, Victor A. Lewis, MD, Ronald Anderson, MDFRCPC, Olga Kovalchuk, MD, PhD, Norman J. Lacayo, MD, Aru Narendran, MD PhD, Kevin J. Bielamowicz, MD

Blood (2019) 134 (Supplement_1): 2633.

https://doi.org/10.1182/blood-2019-131444

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Analysis of a New Haematopoietic Stem/Progenitor Cells with Megakaryocyte Differentiation Potential

Mo Yang, MD, Shichao Chen, Liang Li, PhD, Hongwu Xin, Beng H Chong, MBBS, PhD, Liuming Yang

Blood (2019) 134 (Supplement_1): 4891.

https://doi.org/10.1182/blood-2019-127851

Published: 2019

Journal Articles

Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Kα/β Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a

Lakshmi Reddy Palam, PhD, Baskar Ramdas, PhD, Katelyn Pickerell, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 723.

https://doi.org/10.1182/blood-2019-131036

Published: 2019

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Eric Davis, MD, Felipe Samaniego, MD, Nathan H Fowler, MD, Jason R. Westin, MD, Hun Ju Lee, Michael Wang, MD, Fredrick B. Hagemeister, MD, Philip Beer, MD PhD, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth, PhD

Blood (2019) 134 (Supplement_1): 4099.

https://doi.org/10.1182/blood-2019-130401

Published: 2019

Journal Articles

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma

Changying Jiang, PhD, Rongjia Zhang, Shaojun Zhang, PhD, William Lee, Shengjian Huang, PhD, Yang Liu, MD, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, MBBS,MDDM,PhD, Krystle Nomie, PhD, Linghua Wang, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 4062.

https://doi.org/10.1182/blood-2019-128299

Published: 2019

NARROW

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Analysis of Mechanisms Underlying Clonal Evolution of AML By a New Single-Cell Sequencing Platform

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Signalosome Organization and Platelet Function

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Class I PI3K Is Required for HSC Differentiation

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Analysis of a New Haematopoietic Stem/Progenitor Cells with Megakaryocyte Differentiation Potential

Loss of Dnmt3a Dysregulates Hematopoietic Homeostasis and Myeloid Skewing Via the PI3Kinase Pathway: PI3Kα/β Inhibition Corrects Extramedullary Hematopoiesis and Myeloid Skewing Due to Loss of Dnmt3a

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only